Table III.

Frequency of safinamide off-label use among the Spanish and European study populations at the start of treatment.

Category of off-label use	Spain (n, %)	Europe (n, %)
Any	158 (30.9%)	233 (16.9%)
Patients without motor fluctuations at the start of treatment	86 (16.8%)	121 (8.8%)
Patients that start safinamide with a dose other than 50 mg/day	74 (14.5%)	105 (7.6%)
Patients without levodopa in addition to safinamide	14 (2.7%)	21 (1.5%)
Patients with a diagnosis other than idiopathic PD	11 (2.2%)	16 (1.2%)
Patients treated concomitantly with other MAO inhibitors	7 (1.4%)	11 (0.8%)

Percentages (%) are computed out of the evaluable patients. MAO: monoamine oxidase; n: number of patients; PD: Parkinson’s disease.